Year in cancer

1999 in cancer

What the index holds for 1999: regulatory decisions dated that year, studies first posted that year, PubMed output per cancer for that year and the registry observations whose reference year it is. Every figure is a count of dated source records — nothing is estimated.

Regulatory

Approval records dated 1999 (26)

Approved, accelerated or conditional records by authority; original applications and records naming one cancer are listed first. One record is one decision for one application or product identifier.

FDA · US: 17 records / 12 drugsHealth Canada · CA: 8 records / 4 drugsEMA · EU: 1 records / 1 drugs

Dec 29, 1999Bexarotene FDA · US original application approved Primary Cutaneous T-Cell Non-Hodgkin LymphomaTARGRETIN ® (bexarotene) Capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at…openfda
Oct 21, 1999Exemestane FDA · US original application approved Malignant Breast Neoplasmtreatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ).openfda
Oct 21, 1999Exemestane FDA · US original application approved Malignant Breast Neoplasmadjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are…openfda
Sep 15, 1999Epirubicin FDA · US original application approved Malignant Breast NeoplasmELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast…openfda
Aug 11, 1999Temozolomide FDA · US original application approved Anaplastic AstrocytomaAnaplastic astrocytoma.openfda
Aug 11, 1999Temozolomide FDA · US original application approved Anaplastic AstrocytomaAdjuvant treatment of adults with newly diagnosed anaplastic astrocytoma.openfda
Aug 11, 1999Temozolomide FDA · US original application approved Anaplastic AstrocytomaTreatment of adults with refractory anaplastic astrocytoma.openfda
Aug 11, 1999Temozolomide FDA · US original application approved GlioblastomaNewly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment.openfda
Feb 2, 1999Alitretinoin FDA · US original application approved AIDS-Related Kaposi SarcomaKaposi’s Sarcoma PANRETIN GEL is indicated for topical treatment of cutaneous lesions in adults with AIDS related Kaposi’s sarcoma (KS). Limitations of Use:…openfda
Dec 7, 1999Sertraline FDA · US original application approved cancer not stated in this recordMajor depressive disorder (MDD) • Obsessive-compulsive disorder (OCD) • Panic disorder (PD) • Posttraumatic stress disorder (PTSD) • Social anxiety disorder…openfda
Dec 3, 1999Aminolevulinic Acid FDA · US original application approved cancer not stated in this recordThe LEVULAN KERASTICK for topical solution plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for the…openfda
Sep 15, 1999Sirolimus FDA · US original application approved cancer not stated in this recordPatients at low- to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2–4 months after…openfda
Jan 26, 1999Temozolomide EMA · EU centralised approved GlioblastomaTemodal hard capsules is indicated for the treatment of: adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and…ema
Dec 23, 1999Docetaxel FDA · US supplement approved cancer not stated in this recordEfficacy supplement 1999-12-23 (see label)openfda
Dec 7, 1999Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 1999-12-07 (see label)openfda
Nov 12, 1999Temozolomide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as TEMODAL (DIN 02241096) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
Nov 12, 1999Temozolomide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as TEMODAL (DIN 02241094) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
Nov 12, 1999Temozolomide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as TEMODAL (DIN 02241095) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
Nov 12, 1999Temozolomide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as TEMODAL (DIN 02241093) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
Sep 17, 1999Methotrexate Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as APO-METHOTREXATE (DIN 02182963) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the…health-canada-dpd
Sep 13, 1999Leuprolide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as LUPRON DEPOT (DIN 02239834) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
Sep 13, 1999Leuprolide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as LUPRON DEPOT (DIN 02239833) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
Aug 23, 1999Trastuzumab Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as HERCEPTIN (DIN 02240692) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
Jun 28, 1999Doxorubicin FDA · US supplement approved cancer not stated in this recordEfficacy supplement 1999-06-28 (see label)openfda
Apr 15, 1999Ibuprofen FDA · US supplement approved cancer not stated in this recordEfficacy supplement 1999-04-15 (see label)openfda
Feb 11, 1999Leuprolide FDA · US supplement approved cancer not stated in this recordEfficacy supplement 1999-02-11 (see label)openfda

RegulatoryAll 1999 records with filters →

Clinical research

Studies first posted in 1999

ClinicalTrials.gov oncology studies whose first-posted date falls in the year (all study types unless stated). Cancer attribution uses reconciled conditions over descendants; one study can count for several top-level cancers.

Studies: 128
Interventional: 67
Phase III: 7
Industry-led: 0
With posted results: 10
Countries with sites: 6

By phase (a study with two phases counts in both)
Phase	Studies	Interventional	Industry share
Phase 1	20	20	0%
Phase 2	39	39	0%
Phase 3	7	7	0%
Not applicable / not stated	63	2	0%

Top-level cancers by studies (descendants included)
Cancer	Studies	Phase III
Leukemia	16	2
Non-Hodgkin Lymphoma	14	1
Multiple Myeloma	6	1
Malignant Breast Neoplasm	6	1
Malignant Central Nervous System Neoplasm	4	0
Hodgkin Lymphoma	3	0
Malignant Kidney Neoplasm	3	0
Malignant Ovarian Neoplasm	3	1
Kaposi Sarcoma	3	0
Malignant Lung Neoplasm	2	0
Malignant Prostate Neoplasm	2	0
Malignant Thyroid Gland Neoplasm	1	0

Lead sponsors of interventional studies first posted in 1999
Lead sponsor	Class	Studies	Phase III
National Cancer Institute (NCI)	Nih	37	2
National Heart, Lung, and Blood Institute (NHLBI)	Nih	12	3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Nih	5	0
National Institute of Allergy and Infectious Diseases (NIAID)	Nih	2	0
FDA Office of Orphan Products Development	Fed	2	0
National Eye Institute (NEI)	Nih	2	1
Brigham and Women's Hospital	Other	1	1
State University of New York	Other	1	0
National Center for Research Resources (NCRR)	Nih	1	0
National Human Genome Research Institute (NHGRI)	Nih	1	0

Published source: clinicaltrials · first_posted_date as posted

Research output

PubMed records, 1999

Records matching each top-level cancer's stored PubMed query with a publication year equal to this year, with the previous year for comparison. A count of indexed records, not of scientific impact.

No literature window for 1999

Yearly PubMed windows are computed from 2016 onwards for entities with a stored query.

Registries

Observations with reference year 1999

What registries have published for this year: observations by source, metric and geography. Registries publish with a lag of one to three years.

Geography	Metric	Source	Observations	Cancers
United States	Incidence rate (age-standardized)	cdc-uscs	80	32
United States	Mortality rate (age-standardized)	cdc-uscs	77	31
United States	New cases	cdc-uscs	88	32
United States	Deaths	cdc-uscs	85	31

Open 1999 in the Data explorer →